ARTE Artemis Strategic Investment Corporation

Artes Medical, Inc. (Nasdaq:ARTE), a medical aesthetics company, today announced completion of the enrollment and treatment of patients in the ArteFill� Skin Test study. The Company reports that 498 study participants are enrolled in the study and have received ArteFill Skin Test injections. The lead investigator in the study is David Wilson, M.D., of The Education and Research Foundation in Lynchburg, VA. Each participant in the study received the ArteFill Skin Test and was assessed for a positive hypersensitivity reaction to the skin test. Any adverse events were also collected. The primary endpoint of the study is the Investigator�s clinical determination of a positive skin test reaction with histopathology verification. In addition, subjects will have serum antibody levels against bovine collagen evaluated prior to and after treatment in this study. �We are pleased to announce the completion of enrollment and treatment of patients in this important study,� said Christopher J. Reinhard, Executive Chairman, Artes Medical. �Once all of the data has been fully analyzed, we will determine the appropriate next steps. Positive safety data from this study will be used to support a regulatory submission seeking an amendment to the ArteFill product usage labeling to remove the pre-treatment collagen skin test requirement.� About ArteFill� ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known as smile lines or nasolabial folds. The unique microspheres in ArteFill are not absorbed by the body and therefore provide the first-of-its-kind permanent support for long-lasting wrinkle correction in one to two treatments. ArteFill was approved by the FDA in October 2006 based on data from the Company�s 12-month controlled, randomized, double-masked, multi-center U.S. clinical trial, which compared outcomes for patients treated with ArteFill with those of patients treated with the leading bovine collagen-based filler. At the 6-month evaluation, which was the primary efficacy evaluation period for the clinical trial, the wrinkle correction in patients treated with ArteFill persisted and showed statistically significant improvement compared to the wrinkle correction in the patients treated with the collagen control, who returned to their pretreatment status. The ArteFill patients were also evaluated one year after treatment, demonstrating continued safety and wrinkle correction. In December 2007, the Company announced that ArteFill�s 5-year safety and efficacy data was published in the peer-reviewed publication Dermatologic Surgery "Filler Issue." This publication addresses the robust, long-term, efficacy and safety profile of ArteFill. This 5-year follow-up study included 145 patients who were treated with ArteFill in the Company's U.S. clinical trial. In addition to demonstrating the safety profile of ArteFill, the�study showed statistically significant (p